Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery

Intra-Arterial (IA) Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma (ACPP) and Choroid Plexus Carcinoma (CPC) Prior to Second-Look Surgery

This study will test the safety and efficacy of intra-arterial chemotherapy in subjects with newly diagnosed, residual, or recurrent atypical choroid plexus papilloma and choroid plexus carcinoma prior to a second surgery.

It is believed that intra-arterial chemotherapy will be safe and feasible for this population and will result in decreased tumor size, which may further improve the goals of a second-look surgery.

Study Overview

• Status: Terminated
• Conditions: Choroid Plexus Carcinoma; Atypical Choroid Plexus Papilloma
• Intervention / Treatment: Drug: Melphalan; Drug: Carboplatin; Drug: Topotecan

Detailed Description

The intent of this study is to determine if intra-arterial chemotherapy is a safe and effective option for subjects with atypical choroid plexus papilloma and choroid plexus carcinoma prior to receiving second-look surgery. Angiography occurs when a catheter is inserted through the subjects vasculature to the major vessels that supply cerebral circulation. Subjects on this trial will undergo a a cerebral angiogram to determine the ideal arteries to use for drug infusion. Once identified, chemotherapy will be delivered through the catheter directly to the site of tumor.

• Study Type: Interventional
• Enrollment (Actual): 1
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • New York
    • New York, New York, United States, 10025
      • Weill Cornell Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 second to 100 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Subjects with a histologically confirmed diagnosis of ACPP or CPC that is newly diagnosed, residual or recurrent.
2. Subjects must have a Karnofsky or Lansky Performance Score ≥ 60 % assessed within two weeks prior to enrollment. Karnofsky is used for patients ≥ 16 years and Lansky for those < 16.

3. Subjects must have normal organ and marrow function documented within 14 days of enrollment and within 7 days of the start of treatment as noted below:

   1. Absolute neutrophil count ≥ 1,000/μL
   2. Platelets ≥ 100,000/μL (transfusion independent, defined as not receiving platelet transfusions within a 7-day period prior to enrollment)
   3. Hemoglobin ≥ 8 g/dL (may receive PRBC transfusions)
   4. Total bilirubin < 1.5 times upper limit of normal for age
   5. AST (SGOT)/ALT(SGPT) < 2.5 X institutional upper limit of normal for age
   6. Creatinine clearance or radioisotope GFR ≥ 70 ml/min/1.73m2 or a serum creatinine WNL for age as determined using the Schwartz formula.36
   7. Sodium, Potassium, Calcium and Magnesium < 1.5x institutional ULN
   8. Albumin ≥ 3 g/dL
4. Subjects who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to enrollment.
5. Subjects with neurological deficits should have deficits that are stable for a minimum of 1 week prior to enrollment.

6. If the subject has any of the following therapies, must be at least:

   • 4 weeks post-focal RT (radiation therapy), 3 months post-CSI (craniospinal irradiation)
   • 4 weeks post-myelosuppressive chemotherapy (if post-nitrosoureas, must have 6 weeks therapy)
   • 4 weeks post-monoclonal antibodies
   • 1 week post-targeted therapy
7. If subject has received any previous treatment, all treatment related toxicities should have recovered to < grade 2
8. Subject or parent must sign a written informed consent document according to institutional guidelines.

Exclusion Criteria:

1. Females who are pregnant or lactating.
2. Subjects with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction) likely to interfere with the study procedures or results.
3. Subjects who are receiving any other anticancer or investigational agents.
4. Subjects with uncontrolled seizures.
5. Subjects receiving enzyme inducing anticonvulsants.
6. Subjects with other factors that increase the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome) including heart failure that meets New York Heart Association (NYHA) class II or above.
7. Subjects who have had an allogenic bone marrow transplant < 6 months prior to enrollment or an autologous bone marrow/stem cell transplant < 3 months prior to enrollment.
8. Subjects with multifocal disease or disease that has been disseminated will not be eligible for this study. They will undergo systemic chemotherapy and their disease will be further evaluated prior to be eligible for 2nd look surgery.
9. This study will only enroll subjects with ACPP or CPC and will not enroll subjects with choroid plexus papilloma (CPP). ACPP or CPC subjects with symptomatic hydrocephalus will not be eligible for this study. These subjects will have to be treated for their hydrocephalus and be re-evaluated according to our eligibility criteria in order to be enrolled.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Intra-arterial Chemotherapy; Subjects are pre-treated with heparin, and then given single doses of Melphalan, Carboplatin, and Topotecan consecutively via intra-arterial infusion. Multiple arteries may be used, with the total dose of the drugs remaining the same.	Drug: Melphalan; Given at 0.5 mg/ml.; Drug: Carboplatin; Given at 5 mg/ml.; Drug: Topotecan; Given at 0.2 mg/ml.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Safety of intra-arterial chemotherapy in subjects with ACPP and CPC, measured by the number of serious adverse events that are reported as at least possible related to the intervention that occur in subjects on the trial	Through study completion, a little over a year for each subject

Secondary Outcome Measures

Outcome Measure	Time Frame
The number of successful angiography procedures, determined by examination of vasculature and assessment of catheter placement	On Day 1 of the trial for each subject
The number of patients with a tumor volume reduction response, determined by MRI assessments	Between 4-6 weeks after intra-arterial chemotherapy
The proportion of patients with a tumor volume reduction response, determined by MRI assessments	Between 4-6 weeks after intra-arterial chemotherapy
The number of patients with a tumor vascularity reduction response, determined by MRI assessments	Between 4-6 weeks after intra-arterial chemotherapy
The proportion of patients with a tumor vascularity reduction response, determined by MRI assessments	Between 4-6 weeks after intra-arterial chemotherapy
The success of second look surgery determined by measuring the extent of tumor resection	Around 7 weeks after intra-arterial chemotherapy, during second look surgery
The success of second look surgery determined by amount of blood loss	Around 7 weeks after intra-arterial chemotherapy, during second look surgery
The success of second look surgery determined by percent of blood loss	Around 7 weeks after intra-arterial chemotherapy, during second look surgery

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Extent of pathology correlation to tumor vascularity and tumor viability	Determined by comparison of pathology reports and surgical outcomes	Around 7 weeks after intra-arterial chemotherapy

Collaborators and Investigators

• Sponsor: Weill Medical College of Cornell University
• Investigators: Principal Investigator: Mark Souweidane, M.D., Weill Medical College of Cornell University

Study record dates

Study Major Dates

• Study Start (Actual): May 4, 2023
• Primary Completion (Actual): July 23, 2024
• Study Completion (Actual): December 1, 2025

Study Registration Dates

• First Submitted: July 17, 2021
• First Submitted That Met QC Criteria: August 4, 2021
• First Posted (Actual): August 6, 2021

Study Record Updates

• Last Update Posted (Actual): March 25, 2026
• Last Update Submitted That Met QC Criteria: March 20, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neoplasms by Site; Neoplasms; Neoplasms by Histologic Type; Neoplasms, Glandular and Epithelial; Neoplasms, Squamous Cell; Nervous System Neoplasms; Central Nervous System Neoplasms; Brain Neoplasms; Cerebral Ventricle Neoplasms; Choroid Plexus Carcinoma; Amino Acids, Peptides, and Proteins; Organic Chemicals; Heterocyclic Compounds; Hydrocarbons; Camptothecin; Alkaloids; Coordination Complexes; Amino Acids; Nitrogen Mustard Compounds; Mustard Compounds; Hydrocarbons, Halogenated; Phenylalanine; Amino Acids, Aromatic; Amino Acids, Cyclic; Melphalan; Carboplatin; Topotecan
• Other Study ID Numbers: 20-08022610

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No